LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research note released on Friday morning.

Other analysts have also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Tuesday, January 28th. Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Mizuho lowered their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, LivaNova has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Stock Performance

LivaNova stock opened at $47.68 on Friday. The firm has a 50 day simple moving average of $48.34 and a 200-day simple moving average of $49.60. LivaNova has a 1-year low of $43.15 and a 1-year high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of 113.52 and a beta of 1.00.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.27% of the stock is owned by company insiders.

Institutional Investors Weigh In On LivaNova

A number of hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its holdings in LivaNova by 45.5% during the 4th quarter. Jane Street Group LLC now owns 193,826 shares of the company’s stock worth $8,976,000 after buying an additional 60,613 shares in the last quarter. Freestone Grove Partners LP acquired a new stake in shares of LivaNova in the 4th quarter valued at $23,102,000. Schonfeld Strategic Advisors LLC raised its holdings in shares of LivaNova by 147.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company’s stock valued at $4,582,000 after purchasing an additional 58,911 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of LivaNova by 79.3% in the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock valued at $34,214,000 after purchasing an additional 328,313 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of LivaNova by 11.2% in the 4th quarter. Northern Trust Corp now owns 703,019 shares of the company’s stock valued at $32,557,000 after purchasing an additional 70,630 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.